Your browser doesn't support javascript.
loading
Formula modifications to the Crohn's disease exclusion diet do not impact therapy success in paediatric Crohn's disease.
Landorf, Emma; Hammond, Paul; Abu-Assi, Rammy; Ellison, Samuel; Boyle, Terry; Comerford, Annabel; Couper, Richard.
Afiliação
  • Landorf E; Department of Nutrition, Women's and Children's Hospital, Adelaide, South Australia, Australia.
  • Hammond P; Department of Gastroenterology, Women's and Children's Hospital, Adelaide, South Australia, Australia.
  • Abu-Assi R; Department of Gastroenterology, Women's and Children's Hospital, Adelaide, South Australia, Australia.
  • Ellison S; Department of Gastroenterology, Women's and Children's Hospital, Adelaide, South Australia, Australia.
  • Boyle T; Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.
  • Comerford A; Department of Nutrition, Women's and Children's Hospital, Adelaide, South Australia, Australia.
  • Couper R; Department of Gastroenterology, Women's and Children's Hospital, Adelaide, South Australia, Australia.
J Pediatr Gastroenterol Nutr ; 78(6): 1279-1286, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38623960
ABSTRACT

OBJECTIVES:

The Crohn's disease exclusion diet (CDED) + partial enteral nutrition (PEN) is an emerging diet used to induce clinical remission in children with active Crohn's disease (CD). This study aims to determine the effectiveness of using the CDED+PEN to induce clinical remission in an Australian group of children with active CD using different PEN formulas and incorporating patient dietary requirements.

METHODS:

We retrospectively collected data from children (both newly diagnosed and with existing CD while on therapy) with active CD (Paediatric Crohn's Disease Activity Index [PCDAI] ≥10) and biochemical evidence of active disease (elevated C-reactive protein [CRP], erythrocyte sedimentation rate [ESR] or faecal calprotectin [FC]) who completed at least phase 1 (6 weeks) of the CDED+PEN to induce clinical remission. Data were collected at baseline, Week 6 and Week 12. The primary endpoint was clinical remission at Week 6 defined as PCDAI < 10.

RESULTS:

Twenty-four children were included in phase 1 analysis (mean age 13.8 ± 3.2 years). Clinical remission at Week 6 was achieved in 17/24 (70.8%) patients. Mean PCDAI, CRP, ESR and FC decreased significantly after 6 weeks (p < 0.05). Formula type (cow's milk based, rice based, soy based) did not affect treatment efficacy. A greater than 50% decrease in FC was achieved in 14/21 (66.7%) patients who completed phase 1 and 12/14 (85.7%) patients who completed phase 2 of the CDED+PEN.

CONCLUSIONS:

Formula modifications to the CDED+PEN do not impact the expected treatment efficacy in Australian children with active luminal CD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Indução de Remissão / Doença de Crohn / Alimentos Formulados / Nutrição Enteral Limite: Adolescent / Child / Female / Humans / Male País/Região como assunto: Oceania Idioma: En Revista: J Pediatr Gastroenterol Nutr Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Indução de Remissão / Doença de Crohn / Alimentos Formulados / Nutrição Enteral Limite: Adolescent / Child / Female / Humans / Male País/Região como assunto: Oceania Idioma: En Revista: J Pediatr Gastroenterol Nutr Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália